肿瘤分子靶向治疗
被引量：2
Molecular targeting therapy for cancer
摘要
分子靶向治疗是现代肿瘤治疗领域的突破性进展,代表了肿瘤生物治疗目前的最新发展方向.靶向治疗分为三个层次,即器官靶向、细胞靶向和分子靶向.分子靶向是靶向治疗中特异性最高的层次,它是针对肿瘤细胞内某一蛋白质的分子,某一核苷酸的片段,或者某一基因产物进行的治疗.
出处
《现代消化及介入诊疗》
2004年第3期125-129,共5页
Modern Interventional Diagnosis and Treatment in Gastroenterology
参考文献27
-
1[1]Ko EC, Wang X, Ferrone S. Immunotherapy of malignant diseases.Challenges and strategies. Int Arch Allergy Immunol 2003;132:294-309.
-
2[2]Mc Laughlin P, Grillo-Lopez A J, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin oncol 1998;16:2825-2833.
-
3[3]Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Semin Oncol 2003;30:9-15.
-
4[4]Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol 2002;29:30-35.
-
5[5]Schulz H, Klein S K, Rehwald U. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100:3115-3120.
-
6[6]Nieva J, Bethel k, Saven A. Phase Ⅱ study of rituximab in the treamtment of cladribine-failed patients with hairy cell leukemia.Blood 2003;102:810-813.
-
7[7]Byrd J C, Waselenko J K, Maneatis T J, et al. Rituximab therapy in hematologic malignancy patients with increased infusion-related side effects and rapid blood tumor clearance. J Clin oncol 1999;17:791-795.
-
8[8]What's so special about trastuzumab? Drug Ther Bull 2002;40:65-67.
-
9[9]Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer 2001 ;37:18-24.
-
10[10]Stuer TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004;13:173-183.
同被引文献24
-
1陈志南,邢金良.中国生物技术产业发展报告[M].北京:化学工业出版社,2003:107.
-
2陈慰峰,金伯全.医学免疫学[M].4版.北京:人民卫生出版社,2007.
-
3KO E C,WANG X.Immunotherapy of malignant diseases.Challenges and strategies[J].Int Arch Allergy Immunol 2003,132:294-309.
-
4MCLAUGHLIN P.Rituximab;perspective on single angent experience,and_ future directions in combination trials[J].Crit Reu Oncol/Hemat,2001,40(10):3-6.
-
5COLOMER R,SHAMON L A,TSAI M S,et al.Herceptin; from the bench to the clinic[J].Cancer Invest,2001,19(1):49-53.
-
6KIM J A.Targeted therapies for the treatment of cancer[J].Am J Surg,2003,186(9):264-268.
-
7ZAJA F,TOMADINI V,ZACCARIA A,et al.CHOP-rituximab with pegylat ed llposomal doxorubiein for the treatment of elderly patients with dif-fuse large B-cell lymphoma[J].Leuk Lymphoma,2006,47(10):2174-2180.
-
8KEATING M J,FLINN I,JAIN V,et al.Therapeutic role of alemtuzumab (Campath-1H)in patients who have failed fludarabine:results of a large international study[J].Blood,2002,99(10):3554-3561.
-
9WENDTN C M,RITGEN M,SCHWEIGHOFER C D,et al.Consolidation with alemtuzumab in patients with chroniclymphocytic leukemia(CLL)in first remission-experience on safety a)nd efficacy within a randomized multicenter phase III trial of the German CLL Study Group(GCLLSG)[J].Leukemia,2004,18(6):1093-1101.
-
10CHO HS,MASON K,RAMYAR K X,et al.Structure of the extracellular region of HER-2 alone and in complex with the Heceptin Fab[J].Nature,2003,421:756-760.
-
1张百红,岳红云.肿瘤免疫细胞靶向治疗的研究进展[J].西北国防医学杂志,2015,36(12):816-818. 被引量：1
-
2王昌盛,杨亦彬.SLEB淋巴细胞靶向治疗进展[J].国际皮肤性病学杂志,2009,35(2):79-81.
-
3张百红,岳红云.抗肿瘤靶向药物的分类[J].现代肿瘤医学,2017,25(2):299-303. 被引量：9
-
4冯俊,李丽,杨洪斌,刘世喜.用噬菌体展示技术筛选喉癌细胞靶向肽的研究[J].华西医学,2011,26(12):1844-1847. 被引量：1
-
5贾琳,刘巍.骨唾液蛋白诊断乳腺癌骨转移的临床意义[J].中国肿瘤临床,2004,31(23):1375-1377.
-
6杨柯君.分子靶向治疗[J].上海医药,2012,33(15):46-46.
-
7刘自明,李馨筱,严律南.微球包载携有HSV-TK基因腺病毒肝动脉栓塞治疗的实验研究[J].四川大学学报（医学版）,2009,40(3):462-465. 被引量：1
-
8王刚,叶光华.中药归经与肿瘤靶向治疗[J].现代中西医结合杂志,2009,18(26):3257-3260. 被引量：9
-
9张俞,张常然.肾脏靶向治疗研究进展[J].临床和实验医学杂志,2010,9(24):1901-1903. 被引量：2
-
10郑树,魏启春,沈俐,Erika Bohl Kullberg,Lars Gedda.HER-2靶向硼脂质体的细胞靶向与细胞内分布研究[J].中华放射医学与防护杂志,2005,25(4):312-315.
